Recombinant Mouse TLR4 Fc Chimera Protein, CF

When Recombinant Mouse TLR4 Fc Chimera (Catalog # 9149-TR) is coated at 2 µg/mL (100 μL/well), Recombinant Human MD-2 (Catalog #1787-MD) binds with a typical ED50 of 0.15-0.9 μg/mL.

• Reactivity: Mu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Mouse TLR4 Fc Chimera Protein, CF Summary

• Details of Functionality: Measured by its binding ability in a functional ELISA. When Recombinant Mouse TLR4 Fc Chimera is immobilized at 2 μg/mL, 100 μL/well, the concentration of Recombinant Human MD-2 (Catalog # 1787-MD) that produces 50% of the optimal binding response is approximately 0.15-0.9 μg/mL
• Source: Chinese Hamster Ovary cell line, CHO-derived mouse TLR4 protein
  

  Mouse TLR4 (Asn26-Lys629) Accession # Q9QUK6	DIEGRMDP	Mouse IgG2a (Glu98-Lys330)
  N-terminus		C-terminus

• Accession #: Q9QUK6
• N-terminal Sequence: Asn26
• Structure / Form: Disulfide-linked homodimer
• Protein/Peptide Type: Recombinant Proteins
• Purity: >90%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 96 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 115-137 kDa, reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS.
• Purity: >90%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Reconstitution Instructions: Reconstitute at 500 μg/mL in PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Mouse TLR4 Fc Chimera Protein, CF

• ARMD10
• CD_antigen: CD284
• CD284 antigen
• CD284
• EC 3.2.2.6
• EC:3.2.2.6
• homolog of Drosophila toll
• hToll
• TLR4
• TLR-4
• toll like receptor 4 protein
• TOLL
• toll-like receptor 4

Background

TLR4, also known as CD284, is a 100 kDa type I transmembrane glycoprotein that belongs to the mammalian Toll-Like Receptor family of pathogen pattern recognition molecules. The complex of TLR4 with MD-2 functions as a critical receptor for bacterial endotoxin/lipopolysaccharide (LPS) (1-3). Mature mouse TLR4 consists of a 613 amino acid (aa) extracellular domain (ECD), a 21 aa transmembrane segment, and a 176 aa cytoplasmic domain. TLR4 contains 19 leucine rich repeats in its ECD and one cytoplasmic Toll/IL-1 receptor (TIR) domain (4-6). Within the ECD, mouse TLR4 shares 63% and 83% aa sequence identity with human and rat TLR4, respectively. On monocytes, macrophages, dendritic cells, and B cells, MD‑2 expression is required for cell surface localization of TLR4 and for optimal LPS‑induced TLR4 signaling (7-10). MD‑2 also forms soluble disulfide-linked homo-oligomers which can interact with TLR4 (8). Through a domain separate from its TLR4-binding domain, MD‑2 extracts LPS from circulating CD14‑LPS complexes and carries the LPS into a ternary complex with TLR4 (11-13). The interaction of
MD‑2/LPS with TLR4 induces receptor oligomerization and the triggering of an inflammatory response (2, 14). Increased levels of plasma MD‑2 in septic shock patients sensitizes MD‑2 non-expressing epithelial cells to LPS and promotes widespread tissue inflammation (15).

1. Mukherjee, S. et al. (2016) Braz. J. Infect. Dis. 20:193.
   
2. Plociennikowska, A. et al. (2015) Cell. Mol. Life Sci. 72:557.
3. Erridge, C. (2010) J. Leukoc. Biol. 87:989.
4. Medzhitov, R. et al. (1997) Nature 388:394.
5. Poltorak, A. et al. (1998) Science 282:2085.
6. Qureshi, S.T. et al. (1999) J. Exp. Med. 189:615.
7. Shimazu, R. et al. (1999) J. Exp. Med. 189:1777.
8. Visintin, A. et al. (2001) Proc. Natl. Acad. Sci. USA 98:12156.
9. Akashi, S. et al. (2000) J. Immunol. 164:3471.
10. Nagai, Y. et al. (2002) Nat. Immunol. 3:667.
11. Re, F. and J.L. Strominger (2003) J. Immunol. 171:5272.
12. Kennedy, M.N. et al. (2004) J. Biol. Chem. 279:34698.
13. Gioannini, T.L. et al. (2004) Proc. Natl. Acad. Sci. USA 101:4186.
14. Saitoh, S. et al. (2004) J. Endotoxin Res. 10:257.
15. Pugin, J. et al. (2004) Blood 104:4071.

Publications for TLR4 (9149-TR)(3)

Publications using 9149-TR

• Wang, K;Zhou, Y;Li, M;Chen, Z;Wu, Z;Ji, W;Wang, J;Zhang, Y; Structural elucidation and immunomodulatory activities in vitro of type I and II arabinogalactans from different origins of Astragalus membranaceus Carbohydrate polymers 2024-06-01 [PMID: 38494227] (Bioassay, N/A)
• B Jiang, D Wang, Y Hu, W Li, F Liu, X Zhu, X Li, H Zhang, H Bai, Q Yang, X Yang, J Ben, Q Chen Serum Amyloid A1 Exacerbates Hepatic Steatosis via TLR4 Mediated NF-kappaB Signaling Pathway Molecular Metabolism, 2022-03-03;0(0):101462. 2022-03-03 [PMID: 35247611] (Surface Plasmon Resonance (SPR, Mouse)
• F Liu, X Zhang, P Ling, J Liao, M Zhao, L Mei, H Shao, P Jiang, Z Song, Q Chen, F Wang Immunomodulatory effects of xanthan gum in LPS-stimulated RAW 264.7 macrophages Carbohydr Polym, 2017-04-03;169(0):65-74. 2017-04-03 [PMID: 28504179] (Bioassay)

Bioinformatics

• Uniprot:
  • Q9QUK6()